Article citationsMore>>

Wand, O., Guber, E., Guber, A., Shochet, G. E., Israeli-Shani, L. and Shitrit, D. (2018) Inhaled Tranexamic Acid for Hemoptysis Treatment: A Randomized Controlled Trial. CHEST, 154, 1379-1384.
https://doi.org/10.1016/j.chest.2018.09.026

has been cited by the following article:

• TITLE: Cost Effective Trend in Epistaxis Management

  AUTHORS: Roman Sereda, Whitney Hall

  KEYWORDS: Epistaxis, TXA, Tranexamic Acid, Rhinorocket, Nasal Packing

  JOURNAL NAME: International Journal of Otolaryngology and Head & Neck Surgery, Vol.12 No.3, May 6, 2023

  ABSTRACT: Background: Epistaxis affects much of the population and is a common medical complaint seen across a variety of medical settings. Current standard of care treatment includes a range of options from topical therapy to invasive intranasal device insertion in the absence of on-demand specialist involvement. Aim: The aim of this article is to not only highlight superior outcomes in patients with acute nontraumatic epistaxis that are treated with noninvasive nebulized tranexamic acid instead of more invasive options, but also monetary benefit to the community through reduced costs. Case Presentation: this case report highlights a successful epistaxis resolution with use of tranexamic acid in a 64-year-old female after she was subjected to intranasal device insertion that did not resolve bleeding. Conclusion: Nebulized tranexamic acid is a cost-effective medication that not only reduces rates of recurrence, but it also increases patient satisfaction while minimizing overall healthcare costs, and therefore should be the first choice therapy in uncomplicated epistaxis management.